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Abstract Various studies have correlated apolipoprotein (apo)
A-I, the major component high-density lipoprotein, with protec-
tion against development of cardiovascular disease. Although
apoA-I expression has been previously detected in the liver
and intestine, we have discovered that the human apoA-I gene
is also expressed in the heart. Using transgenic (Tg) mice gen-
erated with the human apoA-I/C-III/A-IV gene cluster and Tg
mice produced with just the 2.2 kb human apoA-I gene, we have
detected signi¢cant levels of apoA-I expression in the heart.
Furthermore, the detection of apoA-I expression in the hearts
of human apoA-I Tg mice indicates that the minimal regulatory
elements necessary for cardiac expression of the gene are lo-
cated near its coding sequence. To determine if the apoA-I gene
is also expressed in the human heart, similar analyses were
performed, where apoA-I expression was found in both adult
and fetal hearts. Furthermore in-depth investigation of the var-
ious regions of human and Tg mouse hearts revealed that the
apoA-I mRNA was present in the ventricles and atria, but not in
the aorta. In situ hybridization of Tg mouse hearts revealed that
apoA-I expression was restricted to the cardiac myocyte cells.
Finally, heart explants and cardiac primary culture experiments
with Tg mice showed secretion of particles containing the human
apoA-I protein, and metabolic labeling experiments have also
detected a 28 kDa human apoA-I protein secreted from the
heart. From these novel ¢ndings, new insights into the role
and function of apoA-I can be extrapolated.
. 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Numerous clinical and epidemiological studies have demon-
strated that the level of high-density lipoprotein (HDL) is an
important cardiovascular risk factor [1] and it has also been
shown that HDL has a protective role against coronary artery
disease [2].
Apolipoprotein (apo) A-I is the major structural and func-
tional protein component of HDL and constituting 75% of
the HDL protein fraction. To a large extent, apoA-I deter-
mines the levels of HDL and protects against the development
of atherosclerosis [3,4]. However, the precise mechanisms of
its antiatherogenic action are not yet fully elucidated. The
main hypothesis proposes that the protein plays a key role
in the reverse cholesterol transport (RCT) pathway by pro-
moting cholesterol e¥ux and activating lecithin cholesterol
acyltransferase [5]. Other evidence suggests that apoA-I pro-
tects the arterial wall against atherosclerosis through antioxi-
dant [6,7], antithrombotic [8] and antiin£ammatory [9,10] ac-
tions.
Studies have shown that overexpression of human apoA-I
in mice increases HDL levels and reduces the atherosclerosis
that is induced by a high-fat, high-cholesterol diet or by the
absence of the apoE gene [11,12]. Moreover, apoA-I de¢cient
mice in an apoB transgenic (Tg) background show more se-
vere atherosclerosis [13]. Transfer of the human apoA-I gene
by recombinant adenovirus increases the HDL concentration
and prevents the development of atherosclerotic lesions in
di¡erent mouse models [14^17].
The human apoA-I gene is grouped together with the apoC-
III, apoA-IV, and apoA-V genes in a cluster located on chro-
mosome 11 [18,19]. The major sites of apoA-I expression are
the liver and intestine. The main control regions involved in
its expression are a proximal promoter/enhancer 250 bp up-
stream of the human apoA-I gene and a distal enhancer lo-
cated 7 kb downstream of the gene, in the 5P region of the
apoC-III gene [3]. In Tg mouse models, the proximal pro-
moter/enhancer is enough to achieve hepatic, but not intesti-
nal, expression [20]. The distal enhancer is required to achieve
intestinal expression [20] and to increase hepatic expression
[21].
We report herein that, in addition to the liver and intestine,
the apoA-I is expressed and secreted by the heart. In our
studies, we observed cardiac expression of human apoA-I in
humans and in two di¡erent previously generated Tg mouse
models [22,23].
2. Materials and methods
2.1. Animal models
Five lines of mice transgenic for the human gene cluster apoA-I/C-
III/A-IV were used: lines 11, 12 and 21 already described [23] and two
recently generated lines, 7 and 25. Transgenic Alliance (IFFA CRE-
DO, Charles River Company, France) furnished line 427 of human
apoA-I Tg mice [22]. Tg lines were established and maintained in a
C57BL/6 genetic background. When not otherwise speci¢ed, experi-
ments with the cluster Tg mice were performed with animals of line
12. Seven-month-old animals were used. Non-Tg littermates were used
as controls. Mice were housed in a temperature-controlled room with
alternating 12 h light (7 a.m.^7 p.m.) and dark periods (7 p.m.^7
a.m.). The animals had access to regular mouse chow (UAR, France)
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and water ad libitum. In the high-fat, high-cholesterol diet experi-
ments, a group of cluster Tg mice were subjected to a diet supple-
mented with 10% cocoa butter and 1.25% cholesterol (TD*88051;
Teklad Premier Laboratory Diets, Madison, WI, USA) for 20 weeks.
All procedures involving animal handling and care were conducted in
accordance with Pasteur Institute Guidelines for Husbandry of Lab-
oratory Mice.
2.2. RNA isolation and Northern blot experiments
After an overnight fast, mice were killed by cervical dislocation and
perfused with phosphate-bu¡ered saline (PBS). The heart, liver, and
intestine were quickly dissected out and immediately frozen in liquid
nitrogen. Total RNA from each organ was isolated using the TRI-
Reagent kit (Euromedex, Sou¡efweyersheim, Belgium). J.J. Mercadier
(INSERM U460, Paris, France) kindly supplied RNA samples from
human. Twenty-four Wg of total RNA was used for Northern blot
analysis by standard procedures [24]. The blots were hybridized with
the 32P-labeled cDNA probes previously described for human apoA-
IV [25] and apoC-III [26]. Human and mouse apoA-I-speci¢c probes
were generated by polymerase chain reaction (PCR) ampli¢cation us-
ing the following primer sets: 5P-CAAGAACGGCGGCGCCAGA-3P
and 5P-GCTCTCCAGCACGGGCAGCAGG-3P to give a 130 bp
probe for human apoA-I; and 5P-GCATGCGCACACACGTA-
GACTCTCT-3P and 5P-CGTCTCCAGCATGGGCATCAGACTA-
3P to give a 215 bp probe for mouse apoA-I. The human ubiquitin
probe (Clontech Laboratories, Inc., Palo Alto, CA, USA) was used as
control. Hybridization was carried out according to the QuickHyb
Hybridization Solution instruction manual (Stratagene, La Jolla,
CA, USA). Autoradiographs were scanned with the NIH Image pro-
gram. Signals were normalized according to the ubiquitin signal. The
results were analyzed with the Statview computer program. Di¡er-
ences were tested by the Student’s t-test, and P6 0.05 was considered
signi¢cant. To analyze apoA-I expression in di¡erent parts of the
human heart, a positively charged membrane with immobilized poly
(A)þ RNAs from fetal and adult human cardiovascular tissues (Clon-
tech Laboratories, Inc., Palo Alto, CA, USA) was hybridized with the
human apoA-I probe described above and with a glyceraldehyde-3-
phosphate dehydrogenase control probe.
2.3. Reverse transcription (RT)-PCR ampli¢cation
Five Wg of total mRNA was reverse transcribed according to the
Super Script II RT protocol (Gibco BRL, France). One-twentieth Wl
of the cDNA product was ampli¢ed by PCR using the primers used to
generate the 130 bp human apoA-I probe and the 215 bp mouse
apoA-I probe described above (30 cycles of: 30 s at 94‡C, 30 s at
60‡C, and 30 s at 72‡C). Tg mouse liver samples were used as a
positive control for the presence of human apoA-I mRNA. A L-actin
control transcript of 279 bp was also ampli¢ed using the primers: 5P-
GTGGGGCGCCCCAGGCACCA-3P and 5P-TGGCCTTGGGGTT-
CAGGGGG-3P. PCR products were separated by 1% agarose gel
electrophoresis and visualized after ethidium bromide staining.
2.4. In situ hybridization
Mouse hearts were dissected in cold PBS, ¢xed in 4% paraformal-
dehyde overnight at 4‡C and embedded in para⁄n. Sections were
hybridized with the riboprobes speci¢c for human or mouse apoA-I
described below. Psoralen^biotin-labeled antisense and sense RNA
probes were transcribed using the BrightStar psoralen^biotin labeling
kit (Ambion, CliniSciences, France), according to the instruction
manual. The antisense and sense probes were obtained by separately
cloning the 130 bp fragment of human apoA-I and the 215 bp frag-
ment of mouse apoA-I (described in Section 2.2) into the vector
pCRII-TOPO (TOPO TA cloning kit, Invitrogen, France). A restric-
tion fragment containing either the Sp6 or T7 promoter was recovered
and the probes were generated using the corresponding polymerases.
The in situ hybridization procedure was adapted from Hemmati-Bri-
vanlou et al. [27]. Streptavidin^alkaline phosphatase conjugate was
used to detect biotinylated probe hybridized to the target mRNA,
and NBT (4-nitrobluetetrazolium chloride) and BCIP (5-bromo-4-
chloro-3-indolyl-phosphate) were used as substrates, generating a
blue/purple color. Samples were examined by light microscopy.
2.5. Metabolic labeling experiments
Hearts of cluster Tg and control mice were dissected from the
thoracic cavity, opened longitudinally, and £ushed with ice-cold in-
cubation medium (methionine and cysteine-free DME, D-0422; Sigma
Chemical Co., St. Louis, MO, USA) supplemented with 7% fetal calf
serum, 1.6 mM glutamate, and 1.6 mM sodium pyruvate). Metabolic
labeling experiments were performed as described [28]: Brie£y, freshly
minced heart tissues of Tg and control mice were ¢rst washed three
times with 1.0 ml of the incubation medium and then incubated in 1.0
ml of labeling medium containing 0.6 mCi [35S]Promix (Amersham
Corp., Arlington Heights, IL, USA). After 4 h incubation at 37‡C, the
minced heart was pelleted by centrifugation and the media was col-
lected. Two hundred Wl of each medium was partially puri¢ed by
immunoprecipitation with antibodies directed against the human
apoA-I (Vector Laboratories, Burlingame, CA, USA) and in the pres-
ence of protein A/G-agarose beads (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA, USA). Once the immunoprecipitates were collected
by centrifugation and the supernatants were discarded, the pellets
were washed ¢ve times with TNEM bu¡er (125 mM NaCl, 50 mM
Tris^HCl pH 7.5, 5 mM EDTA, 0.1% NP-40, 1 mM PMSF) and
resuspended in electrophoresis sample bu¡er (0.5 ml glycerol, 0.25
ml L-mercaptoethanol, 1.5 ml 10% sodium dodecyl sulfate (SDS),
0.6 ml 1.0 M Tris^HCl pH 6.7 and 1 mg bromophenol blue). After
boiling 5 min, samples were centrifuged and supernatants were ana-
lyzed by SDS^polyacrylamide gel electrophoresis (PAGE) and auto-
radiography. The remaining 800 Wl of each radioactive incubation
medium was analyzed by SDS^PAGE. After transfer and autoradiog-
raphy, the membranes were incubated overnight at 4‡C with a
1:10 000 dilution of a polyclonal goat anti-human apoA-I antibody.
This antibody was detected with a 1:6500 dilution of peroxidase-con-
jugated anti-goat IgG (H+L) (Vector Laboratories, Burlingame, CA,
USA) and the ECL detection system (Amersham, Little Chalfont,
UK). Antibodies directed against human apoA-I were shown by
Western blot to interact only with the human protein. No cross-re-
action was observed with samples containing only the mouse, horse or
fetal bovine apoA-I (data not shown).
2.6. Agarose gel electrophoresis
Freshly minced heart tissues of Tg mice were incubated in complete
medium. After 4 h, the incubation medium was analyzed by agarose
gel electrophoresis at 4‡C in 0.75% agarose on Gelbond (FMC, Rock-
land, ME, USA) in 50 mM barbital bu¡er (pH 8.6). Twenty Wl of
media and human plasma (used as a migration control) was loaded
into 1.5 U0.2 cm sample channels [29]. After transfer, species con-
taining apoA-I were immunologically identi¢ed, as described above.
The electrophoretic migration was compared to that of the human
plasma lipoproteins stained with Sudan Black.
2.7. Mouse cardiac myocyte cultures
Cardiac myocytes were obtained from the hearts of 1^3-day-old
mice (cluster Tg or non-Tg littermate), by serial trypsinization of
minced tissue as described [30]. Myocytes were plated at a density
of 400 cells/mm2 in low-glucose DMEM (BioWest) supplemented
with 17% M199 (Sigma), 10% horse serum (Sigma), 5% fetal calf
serum (Gibco), 2 mM glutamine (Gibco) and 50 units/ml penicillin^
streptomicin (Gibco). The human apoA-I cardiac expression for clus-
ter Tg mice was assessed by immunoprecipitation, followed by immu-
nodetection.
3. Results
3.1. Expression of human apoA-I gene in the heart of Tg mice
The human apo expression in the heart was analyzed in
apoA-I/C-III/A-IV gene cluster Tg mice. Cluster Tg mice
were generated using a 33 kb human genomic fragment con-
taining the 17 kb of the apoA-I/C-III/A-IV cluster, 8 kb of its
5P region and about 7 kb of its 3P £anking sequences [23]. The
three previously reported Tg lines (lines 11, 12 and 21) and the
two newly generated lines (7 and 25) expressed the three hu-
man genes in liver and intestine. Northern blot analysis also
revealed the presence of a signi¢cant amount of human apoA-
I mRNA in the heart of all ¢ve Tg lines (Fig. 1A). The
amount of human apoA-I mRNA in the heart was 36% rela-
tive to that measured in the liver. Neither human apoC-III
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nor apoA-IV expression was detected in the heart, even after
long periods of autoradiographic exposure.
To further characterize the DNA sequence necessary for
cardiac apoA-I expression, we analyzed hearts of human
apoA-I Tg mice previously generated by Walsh et al. [22].
The fragment used to generate this apoA-I line is 2.2 kb
long and contains the apoA-I gene, 248 bp of the 5P £anking
region, and 80 bp of the 3P £anking region. We also found
expression of the human apoA-I gene in the heart of these
mice, although to a lesser extent than that observed in cluster
Tg mice (Fig. 1B). The presence of the human apoA-I mes-
senger in the heart of both Tg models was con¢rmed by RT-
PCR (Fig. 1C). The corresponding mouse mRNA was not
detected either in Tg or in control littermate mice (Fig. 1B,C).
3.2. Lipid regulation of the human apoA-I gene in the heart of
cluster Tg mice
Previous reports have shown apoA-I gene expression to be
regulated by lipids in cluster Tg mice [31]. We tested the e¡ect
of a high-fat, high-cholesterol diet on cardiac apoA-I gene
expression in these animals. After 20 weeks, cluster Tg mice
fed with an atherogenic diet showed a signi¢cant increase of
human apoA-I mRNA levels in the heart (¢ve-fold), when
compared with those fed with a standard chow diet (Fig. 2).
3.3. Expression of apoA-I gene in human heart
To test whether the presence of human apoA-I mRNA
observed in the heart of Tg mice re£ects the human gene
expression pattern, we analyzed several samples from human
adult hearts. By Northern blot, we demonstrated clearly that
the apoA-I gene was expressed in all the analyzed human
heart samples (Fig. 3A), while neither apoC-III nor apoA-
IV expression was detected, even after long periods of expo-
Fig. 1. Apo expression in mouse heart. A: Northern blot analysis
of non-transgenic (non-Tg) mice and ¢ve di¡erent lines of cluster
transgenic (cluster Tg) mice: lines 7, 11, 25, 12 and 21. The mem-
branes were hybridized independently with four radioactive probes:
hapoA-I, human apoA-I (exposure time: 2 h); hapoC-III, human
apoC-III (exposure time: overnight); hapoA-IV, human apoA-IV
(exposure time: overnight) and ubiquitin (exposure time: 2 h). B:
Northern blot analysis of non-Tg mice, of cluster Tg mice line 12
and of hapoA-I Tg mice line 427. The membrane was hybridized in-
dependently with three radioactive probes: hapoA-I (exposure time:
2 h), mapoA-I, mouse apoA-I (exposure time: overnight) and ubiq-
uitin (exposure time: 4 h). C: RT-PCR analysis of non-Tg mice, of
cluster Tg mice line 12 and of hapoA-I Tg mice line 427. Experi-
ments were performed with mapoA-I (lanes 1, 4, 7), hapoA-I (lanes
2, 5, 8) and L-actin (lanes 3, 6, 9) primers.
Fig. 2. E¡ect of a high-fat, high-cholesterol diet on cardiac apoA-I
expression. Human apoA-I mRNA levels in hearts of cluster Tg
mice under a standard chow diet or a high-fat, high-cholesterol diet
for 20 weeks. Values, normalized for ubiquitin mRNA levels, are
expressed in arbitrary units and correspond to the meanUS.D. of
¢ve measurements in cluster Tg mice on each diet. Error bars repre-
sent S.E.M. **P6 0.005.
Fig. 3. ApoA-I expression in human heart. A: Northern blot of hu-
man heart mRNA of three di¡erent individuals. The membrane was
hybridized independently with two radioactive probes, hapoA-I and
ubiquitin (exposure time: overnight). B: Representative RT-PCR of
mRNA sample from human heart. Experiments were performed
with mapoA-I (lane 1), hapoA-I (lane 2) and L-actin (lane 3) prim-
ers. C: Northern blot analysis of a commercial membrane contain-
ing poly(A)þ RNAs isolated from human tissues. The membrane
was hybridized with two distinct radioactive probes: hapoA-I (expo-
sure time: 29 days) and glyceraldehyde-3-phosphate dehydrogenase
(exposure time: 3 h).
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sure (data not shown). RT-PCR experiments also con¢rmed
apoA-I expression in human hearts (Fig. 3B). Furthermore,
the analysis of a commercial membrane carrying human car-
diac mRNA from di¡erent subjects and from di¡erent regions
of the heart revealed that the gene was expressed in multiple
regions of the organ. The apoA-I mRNA was clearly found in
the apex, the ventricles, and at a lower level in the atria.
ApoA-I mRNA was also detected in total fetal heart. Inter-
estingly, no expression was observed in the aorta (Fig. 3C).
3.4. Human apoA-I is expressed by cardiac myocytes
In order to identify the cell types responsible for the human
apoA-I expression, we performed in situ hybridization on the
hearts of Tg mice. The results show that the human apoA-I
messenger was found only in cardiac myocytes, in both atria
and ventricles. No expression was detected in endothelial, ¢-
broblast or smooth muscle cells or in any of the aortic cells
(Fig. 4). The same pattern of expression was observed in both
cluster Tg and apoA-I Tg mice. The mouse apoA-I gene ex-
pression was not detected in any heart tissue, whereas it was
clearly evident in the liver (data not shown).
3.5. Human apoA-I synthesis by the heart of Tg mice
To study the synthesis of human apoA-I in the heart,
minced pieces of cluster Tg mouse hearts were incubated in
complete media and the resulting supernatant was subjected
to agarose gel electrophoresis. The results show the appear-
ance of pre-beta particles, as judged by their electrophoretic
mobility and con¢rmed by immunodetection of human apoA-
I (Fig. 5). However, the apoA-I in the secreted particles could
have originated from other tissues and subsequently been
trapped in the heart. To rule out this possibility, primary
cardiac myocyte cultures were developed from hearts of new-
born cluster Tg mice or controls. At 5 days of age, primary
cardiac myocyte cultures from Tg (in which apoA-I mRNA
was previously detected) secreted the human protein in the
media (data not shown). In addition [35S]methionine/cysteine
metabolic labeling experiments were performed on fresh heart
explants from cluster Tg mice and control littermates (Fig. 6).
The incubation media were analyzed by SDS^PAGE and a
faint supplementary radioactive band was found only in the
Tg media (Fig. 6A). The same gel was transferred to a mem-
brane and submitted to a Western blot analysis. Using a spe-
ci¢c apoA-I antibody, we found that the supplementary radio-
Fig. 4. In situ hybridization experiments. Human apoA-I in situ hy-
bridization experiments in sections of heart (A,B) and of aorta
(C,D) of cluster Tg mice, line 12, and in sections of heart of
hapoA-I Tg mice, line 427 (E,F). A,C,E: hapoA-I antisense probe.
B,D,F: hapoA-I sense probe. Positive signals in A and E indicating
the presence of hapoA-I mRNAs in cardiac myocytes appear as pur-
ple staining. Ampli¢cationU400. (For interpretation of the reference
to color in this ¢gure legend, the reader is referred to the web ver-
sion of this article.)
Fig. 5. Analysis of hapoA-I in cluster Tg mice. Agarose gel electro-
phoresis of incubation media of minced heart tissue from Tg mice.
K and L electrophoretic mobilities were positioned after electropho-
resis of human plasma lipids stained with Sudan Black (lane 1).
Western blot of proteins secreted by minced heart tissue of cluster
Tg mice (lane 2). The incubation medium was submitted to agarose
gel electrophoresis and immunoblotted with anti-human apoA-I
antibodies.
Fig. 6. Metabolic labeling experiments. A: SDS^PAGE autoradiog-
raphy of [35S]methionine/cysteine incubation media of minced heart
from cluster Tg mice line 12 (lane 1), from non-Tg mice (lane 2)
and as a control, human apoA-I puri¢ed protein (lane 3). B: West-
ern blot analysis, using a speci¢c anti-human apoA-I antibody, of
the corresponding SDS^PAGE shown in A. C: Metabolic labeling
of hearts from cluster Tg mice line 12 (lane 1) and from non-Tg
mice (lane 2). Minced heart tissues were incubated in the presence
of [35S]methionine/cysteine. The incubation media was partially im-
munoprecipitated and analyzed by autoradiography after SDS^
PAGE separation. Molecular weight markers are indicated on the
left.
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active band corresponded to the human apoA-I protein (Fig.
6B). Aliquots of the incubation media were also partially
puri¢ed by immunoprecipitation using antibodies directed
against human apoA-I and analyzed by SDS^PAGE. The
results show that a 28 kDa radioactive protein with the mo-
lecular weight of apoA-I was present in media from cultures
of Tg but not control heart explants (Fig. 6C).
4. Discussion
In this study, we demonstrate that the human apoA-I gene
is expressed in the heart of humans and in two distinct Tg
mouse models [22,23]. Whereas the human apoA-I, apoC-III,
and apoA-IV genes are expressed in the liver and intestine of
both humans and cluster Tg mice, expression in the heart is a
speci¢c feature only of apoA-I. The relative amount of human
apoA-I mRNA in the heart represents about one-third of the
liver expression. The apoA-I plasmatic level is regulated by a
post-transcriptional mechanism and associated with changes
in HDL distribution [45]. The production of human apoA-I
protein by the heart might therefore be proportionately lower
than the liver secretion.
In situ hybridization analyses showed that the expression of
the human apoA-I gene in the hearts of cluster Tg and apoA-I
Tg mice was restricted to cardiac myocytes. Neither other
cardiac cells nor any aortic cells expressed the human gene.
The human apoA-I transcription was not restricted to certain
areas of the organ, since the presence of the mRNA was
observed in ventricles and atria in adult tissues of both hu-
mans and Tg mice. This cell type-speci¢c expression suggests
that the presence of apoA-I in the heart could be linked to a
cardiac myocyte function. These cells are not expected to syn-
thesize proteins involved in lipoprotein metabolism; however,
it has been shown that they synthesize the apoB and micro-
somal triglyceride transfer protein and consequently are in-
volved in lipid transport regulation [32^34].
We also studied whether the apoA-I protein is synthesized
by the cluster Tg heart. After incubation of Tg mouse hearts
in complete media, particles that displayed a pre-beta HDL
electrophoretic mobility and contained the human apoA-I
protein were secreted. Moreover, 5-day-old primary cultures
of Tg cardiac myocytes secreted human apoA-I into the me-
dia. Finally, when minced pieces of Tg hearts were incubated
in the presence of radioactive precursors and media was par-
tially puri¢ed via immunoprecipitation, a labeled protein with
the apoA-I molecular weight of 28 kDa was observed. The
radioactive band migrating at this position was shown to be
the human apoA-I protein. These results strongly support the
fact that the cardiac myocytes of cluster Tg mice secrete hu-
man apoA-I.
The human apoA-I expression observed in apoA-I Tg mice
indicates that the regulatory elements su⁄cient for the cardiac
expression are contained in a short 2.2 kb genomic fragment
located between 3248 bp upstream and +1934 bp down-
stream of the apoA-I cap site [22]. Therefore, this result dem-
onstrates that the distal enhancer located near the apoC-III
promoter, a locus control region necessary to achieve intesti-
nal expression, is not required for apoA-I heart expression.
Nevertheless, levels of human apoA-I mRNA observed in the
heart of apoA-I Tg mice are lower than in cluster Tg mice.
One explanation could be that the 33 kb DNA fragment used
to generate the cluster Tg mice contains positive regulatory
elements which are lacking in the small 2.2 kb DNA fragment
used in generating the apoA-I Tg mice. One may also
hypothesize hat enhanced apoA-I cardiac expression in clus-
ter Tg mice is a consequence of the hyperlipidemic pro¢le
characteristic of these animals. In fact, it has been reported
that the expression of the gene in cluster Tg mice is in£uenced
by lipids in liver and intestine [31]. Furthermore, after
20 weeks in a high-fat, high-cholesterol diet, cluster Tg mice
exhibited a ¢ve-fold increase in human apoA-I expression in
the heart.
We did not observe expression of the endogenous mouse
apoA-I gene in the heart of control or Tg animals. It is pos-
sible that the expression levels of the mouse mRNA in the
heart are below the detection threshold of the techniques used.
On the other hand, several-fold higher copy numbers of the
human apoA-I transgene could by their numbers alone pro-
duce a higher ‘basal’ mRNA level. Another possible explana-
tion is that, unlike human apoA-I, the mouse gene is not
expressed in this organ. Along this line, it is well known
that the rabbit apoA-I gene, unlike its corresponding gene
in other species, is not expressed in the liver [35].
To try to understand the di¡erential heart expression pat-
tern observed between humans and mice, we aligned the hu-
man and murine promoter sequences [36,37]. We found that
the ¢rst 230 bp upstream of the transcription initiation site of
the human apoA-I gene are highly conserved and present
about 83% homology. In these sequences, we also checked
for the presence of potential motifs that could confer any
cardiac tissue-speci¢c expression. Between nucleotides 361
and 366 bp of the human apoA-I promoter, we localized a
putative binding site (TGATAA) for GATA transcription fac-
tor members that is strictly conserved in mice. Among the
GATA factors, the GATA-4 directs tissue-speci¢c expression
during mammalian cardiac development [38]. In addition,
there is a PPAR-responsive element between nucleotides
3210 and 3190 bp of the human promoter (TGAACC-
CTTGACCCCTGCCCT) [39]. PPARK is a nuclear protein
involved in the control of myocardial lipid metabolism [40]
and is also known to modulate the hepatic expression of
apoA-I [41]. It has been shown in humans that ¢brates, which
activate the PPAR-responsive element, increase plasma levels
of HDL by the induction of apoA-I gene expression [42].
When compared to the PPAR-binding site present in the hu-
man gene, three and four nucleotide di¡erences are observed
in the rat and mouse apoA-I promoters, respectively [39].
Interestingly, these sequence di¡erences abolish the binding
of PPARK. Actually, the mechanisms responsible for the hu-
man apoA-I cardiac gene expression and its absence in mice
seem to be quite complex, and much additional work is
needed to shed light on this matter.
Several studies have indicated that the antiatherosclerotic
mechanisms dependent on apoA-I are related to its promotion
of RCT [43], its antioxidant e¡ect on lipid peroxidation [6,7],
or its inhibition of the expression of endothelial cell adhesion
molecules [9,10]. Although these mechanisms may confer pro-
tection in heart tissue £uids via apoA-I arising from plasma,
apoAI produced by cardiac myocyte cells may intervene as
well. Even in a low proportion, this synthesis may increase
the apoA-I concentration in heart £uids, thereby reinforcing
the protective e¡ect carried out by the plasma protein. Fur-
thermore, it has been reported that even small amounts of
retrovirus-mediated apoA-I synthesis in macrophages protects
FEBS 27957 13-1-04 Cyaan Magenta Geel Zwart
N. Baroukh et al./FEBS Letters 557 (2004) 39^44 43
against atherosclerosis in vivo without modifying plasma
apoA-I and HDL cholesterol levels [44].
While it is believed that the heart is very active in lipid
metabolism, the nature of the lipid-containing particles se-
creted by this organ is not very well known. Recent studies
showing that the heart assembles and secretes apoB-contain-
ing lipoproteins introduced the concept that this organ has
mechanisms for exporting lipids [32^34]. The apoA-I cardiac
synthesis might also be associated with the secretion of lipo-
proteins particles (by myocytes) in an aim to prevent lipid
accumulation in the heart. It is worth noting that apoA-I
may be associated with apoB-secreted lipid particles, which
were found in unusual composition and size in human placen-
tal extracts, as ¢rst described by Park et al. [46]. In this re-
gard, much work needs to be done to determine the nature of
these particles. Overall, we did not notice any obvious ana-
tomical or functional di¡erences between the hearts of Tg
mice expressing the human apoA-I and the wild-type mice
(not expressing any apoA-I).
Our results demonstrate that the human apoA-I gene is
expressed in the heart in humans and in cluster Tg and
apoA-I Tg mice. We also show that the protein is secreted
by cardiac myocytes. Further studies are needed to address
the speci¢c role and physiological relevance of this cardiac
protein.
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